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Objectives: Phenylketonuria (PKU) is an orphan disease with incidence rate 1:5000 
in Egypt. Cost-effectiveness of Sapropterin versus Phenylalanine (PHE) free diet in 
PKU patients from the insurer perspective was evaluated over a time horizon of 10 
years. MethOds: A cohort Markov chain model with six health states: healthy, mild 
PKU, controlled mild PKU, classical PKU, controlled classical PKU and death was 
identified based on the process of the disease. The length of a cycle was set at one 
year. The transition probabilities were derived from updated, previously published 
studies in Egyptian patients with PKU. Relative risk of Sapropterin and utilities were 
derived using international published sources. Direct Medical costs were obtained 
from the Ministry of Health mandatory Tarrif in Egypt. All costs and effects were 
discounted at 3.5% annually. All costs were reported in Egyptian pounds of the 
financial year 2013. Deterministic sensitivity analysis was conducted. Results: 
Total costs for Sapropterin and PHE free diet were 304.1687 EGP and 188.6498 EGP 
respectively. QALYs for Sapropterin and PHE free diet were 0.00566 and 0.00547 
respectively. The incremental cost-effectiveness ratio (ICER) for Sapropterin versus 
PHE free diet was 602,933 EGP/QALY. Sapropterin is not cost effective because it is 
more than 3 times GDP/capita in Egypt (57,566 EGP). The ICER was most sensitive to 
the utility of the states ‘classical PKU’ and ‘controlled classical PKU’. cOnclusiOns: 
World Health Organization recommends that interventions that cost more than 3 
times GDP/capita for one Disability Adjusted Life Year (DALY) avoided should not be 
reimbursed. Despite the difference between DALY and QALY, one can assume they 
are similar to be able to put a value on the outcome. Sapropterin doesn’t represent 
a good value for money compared to PHE free diet in the Egyptian PKU patients.
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Objectives: LighterLife Total (LLT) is a weight loss programme for the obese (BMI 
≥ 30kg/m2) combining a very low calorie diet (VLCD) with weekly support groups 
for behaviour modification. This study evaluated the cost-effectiveness of LLT com-
pared with dietary and surgical interventions. This is the first study assessing the 
cost-effectiveness of a VLCD. MethOds: A cohort model was developed to assess 
the reduction in BMI in the first 12 months following intervention with LLT, gastric 
banding, gastric bypass, Weight Watchers, Counterweight, Slimming World and no 
treatment, and the subsequent yearly BMI increase. Published all cause-mortality was 
applied by age and BMI. Co-morbidity prevalence (diabetes, colorectal cancer, CHD) 
was applied by BMI. Costs were applied for each intervention and for co-morbidities, 
from a UK health care perspective. Utilities were calculated by BMI with an additional 
decrement for co-morbidities. A 10 year time horizon was used. Analyses were run for 
two subgroups: BMI 30-40 in and BMI > 40. Results: BMI 30-40: compared against no 
treatment, Counterweight, Weight Watchers and Slimming World, LLT was associated 
with higher costs, but also greater QALYs and was cost-effective against all, with incre-
mental cost-effectiveness ratios of £14,937, £16,004, £16,182, and £19,840, respectively. 
BMI > 40: compared against no treatment LLT incurred higher costs, but also greater 
QALYs and was cost-effective (ICER = £5,349). LLT was less effective than banding and 
bypass. The budget impact of uptake of LLT across the UK was assessed for both BMI 
30-40 and BMI > 40 groups. cOnclusiOns: BMI 30-40: LLT was more costly than 
dietary interventions, but lead to increased QALYs and was estimated to be cost-effec-
tive. BMI > 40: LLT resulted in a lower initial BMI reduction than gastric banding and 
bypass. LLT was estimated to be cost-effective against no treatment in both groups.
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Objectives: In Italy, within the legal mandate to pursue national self-sufficiency 
of secondary blood products, the Regions are starting to organize trade to off-
set need/availability unbalances. Therefore the determination of the full cost to 
the Regions of plasma collection and handling is needed. MethOds: Plasma 
is obtained from voluntary, non-remunerated donors either from full blood or 
from apheresis, and is collected either directly in facilities of the Regional Health 
Services, or indirectly through the net of donors’ associations before being deliv-
ered to the transformation industry for processing. Amount and costs of materi-
als and activities needed for collecting, producing, validating, and distributing 
plasma were obtained from the transfusional medicine department of the Verona 
province, Veneto Region. Attributable overhead expenses are assumed at 15% of 
direct cost. When plasma is collected as part of the whole blood or from multi-
component apheresis, common costs are attributed basing on the commercial 
value of single components, taken as proxy of the willingness-to-pay for them. 
In an alternative scenario, only product-specific costs are attributed to plasma 
recovered from whole blood donations, for which the driving need is the supply 
of red blood cells. Results: Total cost per liter of plasma sent for processing 
is estimated in 114 and 286 euros, respectively, for collection from whole blood 
and apheresis. Given the current mix of plasma origin, the weighed mean cost 
of plasma to the Regions before processing charges is estimated in 157 € . When 
plasma recovered from whole blood donations is considered by-product, its cost 
per liter sent to industry is estimated in 27 € , and the corresponding weighed 
mean cost in 92 € . cOnclusiOns: The Italian donor-based system, in addition to 
Objectives: To assess cost-effectiveness of PXF, used in combination with G-CSF 
versus standard mobilization options used alone, to enhance mobilization of haema-
topoietic stem cells to the peripheral blood for collection and subsequent autologous 
transplantation (auto-HCT). Target population, as defined by Polish opinion leaders, 
are patients with NHL/HL or MM whose cells mobilize poorly, i.e. predicted poor 
mobilizers (peripheral blood CD34+ cell count < 10/mL) and proven poor mobilizers 
(failure of previous mobilizations). MethOds: PXF is an add-on therapy to currently 
reimbursed standard mobilization (SM) options: G-CSF or chemotherapy plus G-CSF. 
Two scenarios were compared: with and without PXF. Analysis was performed using 
a Markov decision model, developed in TreeAge Pro 2013. A probabilistic (Monte Carlo 
simulation) model with time-dependent transition probabilities included initial 
cycle, during which the individual undergoes mobilization and auto-HCT if cell 
collection is successful, and four mutually exclusive health states: progression-free 
survival (remission and durable remission – lymphomas only), further treatment 
after progression, palliative treatment/observation and death. A one-year Markov 
cycle length was used with half-cycle correction. Baseline cohort characteristics, 
disease progression and utility estimates were obtained from systematic literature 
review and questionnaire study among Polish clinical practitioners. The analysis 
was conducted from the Polish public payer, patients, and societal perspective, over 
a lifetime horizon. Discount rates were 5% (costs) and 3.5% (outcomes). Results: 
The mean QALY gain were 7,378 (PXF) and 6,452 (SM). The mean costs were 188,404 
PLN (€ 45,019) (PXF) and 157,073 PLN (€ 37,532) (SM). Base-case incremental cost-util-
ity ratio (ICUR) in NHL/HL/MM population was 33,821 PLN/QALY (€ 8,082). Probability 
of PXF being cost-effective in Poland when compared to SM is 99,8% (current thresh-
old of 105,801 PLN/QALY (€ 25,281)). cOnclusiOns: Based on accepted cost/QALY 
threshold values in the Polish settings, PXF was proved to be cost-effective option 
for NHL/HL/MM patients with poor response to SM regimens.
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Objectives: To estimate the cost-utility of BEL treatment of patients with SLE as an 
add-on therapy to intensive standard of care (SOC) vs. SOC in Poland. MethOds: 
The general population considered in the analysis were patients with SLE with sig-
nificant disease activity, who met criteria of SLE diagnosis and were ineffectively 
treated with SOC. CUA was performed from the public payer perspective. The lifetime 
horizon was assumed. The decision model was developed in MS Excel and adjusted to 
Polish conditions. The calculations were performed using Monte Carlo microsimula-
tion. The model included data from international clinical studies and Polish data on 
costs and resource utilization. Direct medical costs were included: costs of drugs, 
administration, diagnostic, monitoring and costs related to disease activity. Results were 
calculated for two patients populations: target population 1 (TP1) - patients with 
positive anti-dsDNA, low complement and ≥ 10 scores in SELENA-SLEDAI scale and 
target population 2 (TP2) - patients with positive anti-dsDNA, low complement, ≥ 6 
scores in SELENA-SLEDAI scale and necessity of corticosteroids use. Results: CUA 
results showed that BEL compared to SOC is more costly however, also more effective 
therapy. The ICUR was 113,986 PLN/QALY and 108,744 PLN/QALY, respectively for TP1 
and TP2. Obtained results are placed slightly above the Polish acceptability threshold. 
Additional health effects related to BEL treatment instead of SOC were noticed both 
in LYG and QALY (0.432 and 0.4 LYG; 0.322 and 0.294 QALY, respectively for TP1 and 
TP2). Moreover, the model suggests lower frequency of cardiovascular events, and also 
pulmonary and renal complications in BEL arm. cOnclusiOns: Since there is cur-
rently no effective treatment option of SLE in Poland, reimbursement of belimumab 
will give patients an access to a safe and effective therapy, which allows them to 
return to active life and career and also to improve their quality of life.
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Objectives: To estimate the cost-utility of deferasirox (DSX) treatment of iron over-
load due to frequent blood transfusions in children and adolescents in Polish condi-
tions. MethOds: Clinical effectiveness data were taken from previously performed 
systematic review of deferasirox for the treatment of pediatric patients (age ≤ 18 
years) with iron overload due to frequent blood transfusions. The way of administra-
tion of chelation therapy (parenteral vs. oral) significantly affects patients’ function-
ality and quality of life. Therefore it was decided to perform a cost-utility analysis. 
Analogous to other economic studies, it was assumed that patient survival was the 
same for both compared interventions: deferasirox and deferoxamine (DFO). In the 
analysis a simple decision model was developed. The calculations were performed 
using Monte Carlo microsimulation technique (100,000 trials). Only direct medical 
costs were included in the analysis: costs of drugs and their administration, costs 
of monitoring and costs of blood transfusions. The time horizon of the analysis was 
one-year period. Two perspectives were considered: a public payer (National Health 
Fund, NHF) and the patient and NHF perspective. The measure of effects was QALY 
(quality adjusted life years). Results: The results showed that DSX compared to 
current standard treatment of iron overload due to frequent blood transfusions 
(DFO) in the children and adolescents is more costly however also more effective 
therapy from both considered perspectives. The ICUR (incremental cost-utility ratio) 
of replacing DFO by DSX was 26,180 PN/QALY from NHF perspective. The results from 
both patient and NHF perspective was similar. cOnclusiOns: With reference to 
the acceptability threshold in Poland the oral chelation therapy in the population 
of children and adolescents with iron overload due to frequent blood transfusions 
with deferasirox is cost effective intervention when compared with deferoxamine.
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with rituximab iv preparation and administration, per treatment cycle, was about 89 
minutes versus 16 minutes estimated for sc. An average overall cost reduction of 93% 
was estimated with sc versus iv (3€ versus 45€ , respectively). DCU chair time capacity 
could be increased by 3 and 7 fold if one considers combination or maintenance 
therapy, respectively, with rituximab sc versus iv, due to SC much faster administra-
tion. Rituximab sc reduces the overall time patients spend in an infusion chair by 
95% (7 min with sc vs.143 min with iv). cOnclusiOns: Rituximab sc formulation 
potentially offers significant resource (material and HCP time) savings, improves 
hospital organization and provides clear benefits for patients regarding time saved 
and administration convenience. Ultimately, rituximab sc increases hospital effi-
ciency that’s critical in the current economic climate.
SYStEmiC DiSorDErS/ConDitionS – Patient-reported outcomes &  
Patient Preference Studies
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Objectives: Pain is an important driver of health-related utility. Our purpose was to 
characterise the association between pain severity and the EQ-5D index. MethOds: 
Paired values for the Numerical Pain Rating Scale (NPRS) average pain score (previ-
ous 24 hours) and the EQ-5D index were available from a prospective, non-inter-
ventional study of people with neuropathic pain treated with an 8% capsaicin patch 
(QutenzaTM). The NPRS records pain on an integer scale between 0 and 10 units, 
representing no pain and worst imaginable pain, respectively. The EQ-5D index 
is derived from impairment level (none/moderate/severe) across five domains 
(Mobility, Self-care, Usual activities, Pain & discomfort, Anxiety & depression), and 
values health-related utility on a scale of 1 to 0, meaning perfect health and death, 
respectively. Generalized linear mixed models with a normal probability distribu-
tion, identity link function, and a first-order autoregressive covariance structure 
were tested to determine the relationship between EQ-5D index score (scale) and 
NPRS average 24 hour pain score (ordinal). Results: For the purposes of this pre-
liminary analysis, 170 patients with NP contributed 353 combined observations from 
baseline observation and follow-up assessments at week-8 and week-12. The GLMM 
model that best fitted the data (smallest Information criterion) had one random 
effect (subject + intercept) and one fixed effect (NPRS + intercept). The fixed-effects 
coefficients were: (Intercept) 0.728 + (NPRS1: β 0.000; 95%CI -0.0186, 0.186) + (NPRS2: 
-0.045;-0.205,0.116) + (NPRS3: -0.075;-0.227,0.078) + (NPRS4: -0.207;-0.364,-0.049) + 
(NPRS5: -0.181;-0.338,-0.024) + (NPRS6: -0.315;-0.471,-0.159) + (NPRS7: -0.323;-0.478,-
0.167) + (NPRS8: -0.458;-0.618,-0.299) + (NPRS9: -0.638;-0.825,-0.451) + (NPRS10: -0.740; 
-0.927,-0.553). Predicted utility was highly correlated (R2= 0.753) with observed util-
ity. Mean squared error for predicted utility was 0.033 (sd 0.052). cOnclusiOns: 
Neuropathic pain was highly correlated with utility with a difference of around 
0.8 utility units across the NPRS range. All domains of the EQ-5D differed across 
the NPRS.
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Objectives: Health care payers are interested in funding bariatric surgery because 
it resolves a range of obesity-related health problems. However, following weight 
loss, many patients are left with unsightly excesses of skin and require body-con-
touring surgery. Our team has developed a new PRO instrument (i.e., the BODY-Q) 
to measure satisfaction and quality of life of bariatric and body-contouring surgery 
patients. Unlike existing PRO instruments, the BODY-Q is composed of scales that 
measure appearance-related concerns, which is an important reason why patients 
seek treatment. The BODY-Q also stands apart as it the only PRO instrument designed 
to measure change in patients concerns throughout the entire weight loss jour-
ney. MethOds: We followed international guidelines for the development of a PRO 
instrument. This abstract presents Phase I results, i.e., qualitative phase. Patient 
stories were used to develop a conceptual framework covering the key concerns of 
patients, and to develop a set of preliminary items. Items were grouped into clinically 
meaningful scales and instructions and four-point response options were developed. 
The scales were refined by obtaining feedback from a sample of surgical experts and 
patients. Results: From 59 patient interviews, we developed a conceptual frame-
work. Over 3,500 preliminary items were developed and used to inform the following 
17 independently functioning scales: 1) appearance scales measuring the body, abdo-
men, upper arms, buttocks, inner thighs, hip and outer thighs, skin and scars; 2) qual-
ity of life scales measuring body image, sexual, psychological and social wellbeing, 
physical function and symptoms; and 3) process of care scales measuring satisfaction 
with information, doctor and office staff. cOnclusiOns: Phase II involves a multi-
centered field-test in Canada and the USA. Rasch Measurement Theory analysis will 
be used to determine which items to retain in each scale based on their performance 
against a standard set of psychometric criteria.
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its ethical and social values, supplies plasma at a lower or comparable cost than 
commercially available.
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Objectives: To estimate indirect costs of systemic lupus erythematosus (SLE) in 
Poland, based on absenteeism in the workplace data derived from Department of 
Statistics of the Social Insurance Institution (ZUS). MethOds: Available insurance 
information consisted of data on: (1) sick leaves, (2) short-term inability to work - on 
the basis of decisions authorizing rehabilitation services (3) long-term inability to 
work – on the basis of medical certificates awarded because of incapacity for work. 
To calculate indirect costs we used three parallel alterations of the human capital 
approach (HCA) method - based on: the average monthly gross earnings, Gross 
Domestic Product (GDP) per capita or gross value added per 1 employee (adjusted 
by a factor of marginal productivity of labor). Results: In 2010, in patients with SLE 
in Poland, sick leaves, short-term and long-term inability to work were responsible 
for: 1897, 596 and 27 012 months of absenteeism, in 1600, 112 and 2481 persons, 
respectively. The total number of 2459 years of lost productivity corresponded to 
indirect costs of: 100,421,579 PLN, 97,215,041 PLN or 161,743,804 PLN, based on 
average earnings, GDP per capita or adjusted gross value added per employee, 
respectively. cOnclusiOns: Two of the three approaches, in addition - the most 
frequently mentioned in the literature, indicated the indirect costs of systemic lupus 
erythematosus in Poland at around 100 million PLN per year. Our estimates of indi-
rect costs may be undervalued because it did not include the cost of lost productivity 
due to premature mortality in the course of SLE, and the costs associated with a 
reduction in the efficiency of the work done despite of the disease (preseenteism).
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Objectives: TTR amyloidosis, a progressive, degenerative ultra-rare genetic disease, 
can cause familial amyloid polyneuropathy (TTR-FAP) and cardiomyopathy (TTR-CM), 
requiring substantial caregiver support. This study evaluated the burden of illness 
on patients’ and caregivers’ work productivity, health care resource use (HCRU), and 
health-related quality of life (HRQoL). MethOds: An online survey including the 
Work Productivity & Activity Impairment (WPAI) questionnaire, EQ-5D, & HCRU ques-
tions recruited TTR-FAP and TTR-CM patients and caregivers through two U.S.-based 
patient advocacy groups. Results: Thirty-three TTR patients (26 males) and 18 car-
egivers (7 males) completed the survey. Most were aged over 60; mean disease dura-
tion was approximately 6 years (patients) or 5 years (caregivers with disease). Most 
patients and caregivers had a college degree. Generally caregivers (77.8%) were the 
primary caregiver for their patient; 61.1% also had amyloidosis. Unemployment was 
high in patients with TTR-FAP (42.9%), TTR-CM (60.0%), both TTR-FAP/CM (71.4%); only 
33.3% of caregivers reported working part/full-time. Employment was highest for TTR-
FAP patients (n= 10), yet 11.8% missed work, 32.2% were impaired at work and 38.5% 
reported overall work impairment due to TTR. Liver transplant, the primary treatment 
option, occurred in 42.4% patients and 18.2% caregivers with disease. A majority of 
patients reported outpatient visits to health care providers in the past 3 months for 
disease: 85.7% TTR-FAP, 100% TTR-CM, and 85.7% for TTR-FAP/CM. Hospitalization 
rates ranged from 14.3-30.0% across all patient groups, with 14.3-23.8% for emer-
gency visits. EQ-5D Index scores for patients were 0.80 (SD= 0.14) with transplant, 
and 0.68 (SD= 0.16) without transplant. Caregivers with disease and transplant had 
lower EQ-5D Index scores (M= 0.14, SD= 0.35) than those without transplant (M= 0.41, 
SD= 0.32). The pattern was similar for EQ-5D VAS results for patient and caregiver 
groups. cOnclusiOns: TTR amyloidosis is associated with substantial disruption 
in employment rates, work productivity, high levels of resource use, and poor HRQoL 
for patients and caregivers.
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Objectives: Determine the costs associated with rituximab intravenous (iv) prepa-
ration and administration in follicular non-Hodgkin lymphoma (NHL) and estimate 
the difference versus rituximab subcutaneous (sc) formulation, considering material 
resources (MR) consumption and health care professionals (HCP) time spent in each 
procedure. Patient’s and chair time savings in hospital Day Care Unit (DCU) were 
also estimated. MethOds: Rituximab iv data was collected, between November 
2012 and January 2013, through face to face interviews with pharmacists and DCU 
nurses responsible for the preparation and administration in each hospital. The HCP 
time cost was calculated by multiplying their income per hour by the average time 
spent on each procedure; MR costs were determined based in official databases or 
in “table values” provided by the manufacturers. Rituximab sc administration time 
was based in the respective pivotal clinical trial - SABRINA (BO22334). Results: 
Ten hospitals from mainland Portugal were included, with a weekly average of 7 
NHL patients treated with rituximab iv. The HCP average overall active time spent 
